OIA
BIB icon

Optimum Investment Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Optimum Investment Advisors’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-600
Closed -$28K – 920
2014
Q2 		$28K Hold
600
– – 0.01% 599
2014
Q1 		$24K Buy
+600
New +$27.2K 0.01% 485

Other funds holding BIB

VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
ABI
Adamant Biomedical Investments Zurich, Switzerland $418M AUM
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Flow Traders U.S.
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

Optimum Investment Advisors's BIB Position: Q3 2014 in Review

Optimum Investment Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2014, closing a stake of 600 shares — an estimated $28K sold.

Optimum Investment Advisors first reported a position in BIB in Q1 2014 and held it in 2 quarters. The position peaked at $28K in Q2 2014. 17 funds tracked by Wall St. Rank hold BIB as of Q3 2014.

  • Optimum Investment Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2014 after selling out during the quarter.
  • Optimum Investment Advisors sold 600 ProShares Ultra NASDAQ Biotechnology shares in Q3 2014, an estimated $28K.
  • Optimum Investment Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 2 quarters.
  • Optimum Investment Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $28K in Q2 2014.
  • 17 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2014.

Based on Optimum Investment Advisors's 13F filing for Q3 2014, filed 17 Nov 2014.